Ulcerative Colitis Market Is Expected to Reach $10.8 Billion by 2030

Ulcerative colitis market was valued at $6.2 billion in 2020, and is estimated to reach $10.8 billion by 2030, growing at a CAGR of 5.7% from 2021 to 2030. The report provides an in-depth analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive scenario, and varying market trends.

𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :
The key market players analyzed in the global ulcerative colitis market report include Ajinomoto, AstraZeneca PLC., Eli-Lilly, GlaxoSmithKline Plc., Abbott Laboratories, Johnson & Johnson, Merck & Co., Sanofi Index Pharmaceuticals Holdings AB, and Pfizer Inc.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/3965

Covid-19 scenario-

• Patients across the world were forced to either cancel or delay elective surgeries, including elective procedures for IBD (Inflammatory Bowel Disease). This, in turn, impacted the global ulcerative colitis market negatively.
• Also, postponement of procedures for ulcerative colitis treatment gave way to a steep decline in the production of medications for ulcerative colitis disease.

Based on molecule type, the small molecules segment contributed to nearly three-fourths of the total market revenue in 2020, and is projected to lead the trail by 2030. The same segment would also exhibit the fastest CAGR of 6.0% during the forecast period.

Based on region, the market across North America held the major share in 2020, garnering more than two-fifths of the global market. The Asia-Pacific region, simultaneously, would manifest the fastest CAGR of 6.5% throughout the forecast period. The report also analyzes other regions that including Europe and LAMEA.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 https://www.alliedmarketresearch.com/purchase-enquiry/3965

𝐊𝐄𝐘 𝐅𝐈𝐍𝐃𝐈𝐍𝐆𝐒 𝐎𝐅 𝐓𝐇𝐄 𝐒𝐓𝐔𝐃𝐘

• By disease type, the mild UC segment was the highest contributor to the market in 2020.
• On the basis of molecule type, the small molecule segment dominated the market in 2020, and is expected to continue this trend during the forecast period.
• On the basis of route of administration, the oral segment dominated the market in 2020, and is expected to continue this trend during the forecast period
• Region wise, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:

Transcriptomics Market -- https://www.alliedmarketresearch.com/transcriptomics-market

Biobanking Market -- https://www.alliedmarketresearch.com/biobanking-market

Contact:

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.